Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) is paving the way for large-scale, next-generation sequencing-based (NGS) COVID-19 testing. Today, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Illumina COVIDSeq™ Test, a high-throughput, sequencing-based, in vitro diagnostic (IVD) workflow enabling the detection of SARS-CoV-2. The end-to-end workflow extends the options... Read more

Blocking Radiation in Wearable Devices

Researchers use scanning electron microscopy (SEM) to characterize a lightweight, flexible material with high performance shielding capabilities From wearable fitness trackers, such as smartwatches, to wearable healthcare devices, such as ECG and blood pressure monitors, there is a rising demand for increasingly advanced wearable devices. Devices such as these are packed with highly integrated circuits,... Read more

PerkinElmer Extends Dairy Analysis Portfolio with Smaller Footprint, Full Spectrum FT-IR Spectrometry Solution for Milk, Whey and Cream

Lactoscope™ FT-B instrument provides accurate, cloud-connected testing and results in under 45 seconds WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today launched the LactoScope™ FT-B instrument, which delivers quick and accurate full spectrum component testing and adulterant screening for liquid dairy products such as whey, raw and skim milk, shelf... Read more

Illumina, Inc. and the Illumina Corporate Foundation Commit $10 Million to COVID-19 Response and Research

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) is committed to supporting the global, national and local relief efforts of our customers, employees and communities, as we unite to combat COVID-19. Giving back is in our DNA, and together with the Illumina Corporate Foundation, we have committed more than $10M to support the communities where we live... Read more

Danaher Announces Pricing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering

Danaher Announces Pricing Of Common Stock Offering And Mandatory Convertible Preferred Stock Offering WASHINGTON, May 8, 2020 /PRNewswire/ — Danaher Corporation (NYSE:DHR) (“Danaher”) announced today that it has priced concurrent offerings of 9,509,203 shares of common stock at a price to the public of $163.00 per share and 1,550,000 shares of 5.00% Series B Mandatory Convertible Preferred... Read more

Danaher Announces Offerings Of Common Stock And Mandatory Convertible Preferred Stock

Danaher Announces Offerings Of Common Stock And Mandatory Convertible Preferred Stock WASHINGTON, May 7, 2020 /PRNewswire/ — Danaher Corporation (NYSE:DHR) (“Danaher”) announced today that it has commenced concurrent offerings of $1.25 billion of shares of common stock and $1.25 billion of shares of Series B Mandatory Convertible Preferred Stock, subject to market and other conditions (the offerings).... Read more

Danaher Reports First Quarter 2020 Results

WASHINGTON, May 6, 2020 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the quarter ended April 3, 2020.  All results in this release reflect only continuing operations unless otherwise noted. For the first quarter 2020, net earnings were $595.1 million, or $0.81 per diluted common share.  Non-GAAP adjusted diluted net earnings... Read more

PerkinElmer Announces Financial Results for the First Quarter of 2020

Revenue of $652.4 million; 1% reported growth; (1)% organic growth GAAP EPS from continuing operations of $0.30; Adjusted EPS of $0.67 Withdrawing previously disseminated FY20 guidance due to COVID-related uncertainties WALTHAM, Mass.–(BUSINESS WIRE)–May 5, 2020– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the... Read more

Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development

SAN DIEGO–(BUSINESS WIRE)–Illumina (NASDAQ: ILMN) today announced the appointment of Alex Aravanis as Chief Technology Officer. Dr. Aravanis will be responsible for leading Illumina’s research and technology development functions and the innovation engine for next-generation sequencing platforms and applications, accelerating technology breakthroughs and translation to the clinic. Dr. Aravanis will join Illumina in early June... Read more